These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 23312471)

  • 1. Identification of N-acyl 4-(3-pyridonyl)phenylalanine derivatives and their orally active prodrug esters as dual acting α4β1 and α4β7 receptor antagonists.
    Tilley JW; Sidduri A; Lou J; Kaplan G; Tare N; Cavallo G; Frank K; Pamidimukkala A; Choi DS; Gerber L; Railkar A; Renzetti L
    Bioorg Med Chem Lett; 2013 Feb; 23(4):1036-40. PubMed ID: 23312471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of N-acyl 4-(5-pyrimidine-2,4-dionyl)phenylalanine derivatives and their orally active prodrug esters as dual-acting alpha4-beta1 and alpha4-beta7 receptor antagonists.
    Sidduri A; Tilley JW; Lou J; Tare N; Cavallo G; Frank K; Pamidimukkala A; Choi DS; Gerber L; Railkar A; Renzetti L
    Bioorg Med Chem Lett; 2013 Feb; 23(4):1026-31. PubMed ID: 23312474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists.
    Gong Y; Barbay JK; Dyatkin AB; Miskowski TA; Kimball ES; Prouty SM; Fisher MC; Santulli RJ; Schneider CR; Wallace NH; Ballentine SA; Hageman WE; Masucci JA; Maryanoff BE; Damiano BP; Andrade-Gordon P; Hlasta DJ; Hornby PJ; He W
    J Med Chem; 2006 Jun; 49(11):3402-11. PubMed ID: 16722660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist.
    Chanteux H; Staelens L; Mancel V; Gerin B; Boucaut D; Prakash C; Nicolas JM
    Drug Metab Dispos; 2015 Sep; 43(9):1381-91. PubMed ID: 26153275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A small molecule, orally active, alpha4beta1/alpha4beta7 dual antagonist reduces leukocyte infiltration and airway hyper-responsiveness in an experimental model of allergic asthma in Brown Norway rats.
    Cortijo J; Sanz MJ; Iranzo A; Montesinos JL; Nabah YN; Alfón J; Gómez LA; Merlos M; Morcillo EJ
    Br J Pharmacol; 2006 Mar; 147(6):661-70. PubMed ID: 16432509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalanine (MK-0617), a highly potent and orally active VLA-4 antagonist.
    Venkatraman S; Lebsack AD; Alves K; Gardner MF; James J; Lingham RB; Maniar S; Mumford RA; Si Q; Stock N; Treonze KM; Wang B; Zunic J; Munoz B
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5803-6. PubMed ID: 19713111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro hydrolysis and transesterification of CDP323, an α4β1/α4β7 integrin antagonist ester prodrug.
    Chanteux H; Rosa M; Delatour C; Prakash C; Smith S; Nicolas JM
    Drug Metab Dispos; 2014 Jan; 42(1):153-61. PubMed ID: 24179032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small molecule alpha4beta1/alpha4beta7 antagonist differentiates between the low-affinity states of alpha4beta1 and alpha4beta7: characterization of divalent cation dependence.
    Egger LA; Cao J; McCallum C; Kidambi U; Van Riper G; McCauley E; Mumford RA; Lanza TJ; Lin LS; de Laszlo SE; Young DN; Yang G; Dean DC; Raab CE; Wallace MA; Jones AN; Hagmann WK; Schmidt JA; Pepinsky RB; Scott DM; Lee WC; Cornebise MA; Detmers PA
    J Pharmacol Exp Ther; 2003 Sep; 306(3):903-13. PubMed ID: 12766251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orally available and efficacious α4β1/α4β7 integrin inhibitors.
    Xu YZ; Smith JL; Semko CM; Rossiter KI; Fukuda JY; Dappen MS; Quincy DA; Konradi AW; Mao W; Welch B; Dreyer ML; Samant B; Zhang H; Lugar J; Liao Z; Henschel C; Petersen E; Vandevert C; Shoemaker M; Wehner N; Mutter L; Shopp G; Krimm M; Chen L; Wipke B; Dofiles L; Gallager I; Sauer JM; Messersmith EK; Pleiss MA; Bard F; Yednock TA
    Bioorg Med Chem Lett; 2013 Aug; 23(15):4370-3. PubMed ID: 23777782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and SAR of N-benzoyl-L-biphenylalanine derivatives: discovery of TR-14035, a dual alpha(4)beta(7)/alpha(4)beta(1) integrin antagonist.
    Sircar I; Gudmundsson KS; Martin R; Liang J; Nomura S; Jayakumar H; Teegarden BR; Nowlin DM; Cardarelli PM; Mah JR; Connell S; Griffith RC; Lazarides E
    Bioorg Med Chem; 2002 Jun; 10(6):2051-66. PubMed ID: 11937364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aza-bicyclic amino acid carboxamides as alpha4beta1/alpha4beta7 integrin receptor antagonists.
    Dyatkin AB; Gong Y; Miskowski TA; Kimball ES; Prouty SM; Fisher MC; Santulli RJ; Schneider CR; Wallace NH; Hornby PJ; Diamond C; Kinney WA; Maryanoff BE; Damiano BP; He W
    Bioorg Med Chem; 2005 Dec; 13(24):6693-702. PubMed ID: 16112583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-acyl phenylalanine analogues as potent small molecule VLA-4 antagonists.
    Chen L; Tilley JW; Huang TN; Miklowski D; Trilles R; Guthrie RW; Luk K; Hanglow A; Rowan K; Schwinge V; Wolitzky B
    Bioorg Med Chem Lett; 2000 Apr; 10(8):725-7. PubMed ID: 10782673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
    Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
    Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent in vivo suppression of inflammation by selectively targeting the high affinity conformation of integrin α4β1.
    Vanderslice P; Woodside DG; Caivano AR; Decker ER; Munsch CL; Sherwood SJ; Lejeune WS; Miyamoto YJ; McIntyre BW; Tilton RG; Dixon RA
    Biochem Biophys Res Commun; 2010 Oct; 400(4):619-24. PubMed ID: 20807504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist.
    Muro F; Iimura S; Yoneda Y; Chiba J; Watanabe T; Setoguchi M; Iigou Y; Takayama G; Yokoyama M; Takashi T; Nakayama A; Machinaga N
    Bioorg Med Chem; 2008 Dec; 16(23):9991-10000. PubMed ID: 18952443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4.
    Lin LS; Lanza T; Jewell JP; Liu P; Jones C; Kieczykowski GR; Treonze K; Si Q; Manior S; Koo G; Tong X; Wang J; Schuelke A; Pivnichny J; Wang R; Raab C; Vincent S; Davies P; Maccoss M; Mumford RA; Hagmann WK
    J Med Chem; 2009 Jun; 52(11):3449-52. PubMed ID: 19441819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and metabolism of TR-14035, a novel antagonist of a4ss1/a4ss7 integrin mediated cell adhesion, in rat and dog.
    Tsuda-Tsukimoto M; Ogasawara Y; Kume T
    Xenobiotica; 2005 Apr; 35(4):373-89. PubMed ID: 16019958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-Tetrahydrofuroyl-(L)-phenylalanine derivatives as potent VLA-4 antagonists.
    Yang GX; Chang LL; Truong Q; Doherty GA; Magriotis PA; de Laszlo SE; Li B; MacCoss M; Kidambi U; Egger LA; McCauley E; Van Riper G; Mumford RA; Schmidt JA; Hagmann WK
    Bioorg Med Chem Lett; 2002 Jun; 12(11):1497-500. PubMed ID: 12031328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a potent, orally bioavailable pyrimidine VLA-4 antagonist effective in a sheep asthma model.
    Semko CM; Chen L; Dressen DB; Dreyer ML; Dunn W; Farouz FS; Freedman SB; Holsztynska EJ; Jefferies M; Konradi AW; Liao A; Lugar J; Mutter L; Pleiss MA; Quinn KP; Thompson T; Thorsett ED; Vandevert C; Xu YZ; Yednock TA
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1741-3. PubMed ID: 21316228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-(arylacetyl)-biphenylalanines as potent VLA-4 antagonists.
    Li B; de Laszlo SE; Kamenecka TM; Kopka IE; Durette PL; Lanza T; MacCoss M; Tong S; Mumford RA; McCauley ED; Van Riper G; Schmidt JA; Hagmann WK
    Bioorg Med Chem Lett; 2002 Aug; 12(16):2141-4. PubMed ID: 12127523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.